Jean-Pierre Lindenmayer, MD
Enriched profileClinical Professor, Department of Psychiatry, NYU Grossman School of Medicine; Director, Manhattan Schizophrenia Research Program (Manhattan Psychiatric Center / Nathan Kline Institute for Psychiatric Research) · NYU Grossman School of Medicine
Jean-Pierre Lindenmayer is Clinical Professor, Department of Psychiatry, NYU Grossman School of Medicine; Director, Manhattan Schizophrenia Research Program (Manhattan Psychiatric Center / Nathan Kline Institute for Psychiatric Research) at NYU Grossman School of Medicine. ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 1 Sept 2026
Jean-Pierre Lindenmayer, MD, is Clinical Professor, Department of Psychiatry, NYU Grossman School of Medicine. The public record shows 49 publications with 5,394 citations (h-index 34), centered on Bipolar Disorder, Schizophrenia. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 7 companies, 3 NIH-funded awards (1993–2025).
- Top research focus: Bipolar Disorder
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 7 companies
Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 1 Sept 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- A Virtual Reality Mindfulness Application for Aggression in Schizophrenia
Sponsor: Manhattan Psychiatric Center
- Can Cognitive Training Decrease Reactive Aggression?
Sponsor: Weill Medical College of Cornell University
- Transcranial Direct-current Stimulation (tDCS) in Treatment Refractory Auditory Hallucinations
Sponsor: Manhattan Psychiatric Center
Industry payments
Updated 1 Sept 2026
7 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Mylan Inc.Program year20251 payment
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- Aurobindo Pharma USA, Inc.Program year20241 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
92.2%SNRI22.3%Duloxetine Hcl63%Venlafaxine Hcl Er37%Part D<11 patientsBenzodiazepine16%Lorazepam67%Clonazepam33%Part D<11 patientsMetabolism & gastrointestinal
7.8%Biguanide (metformin)7.8%Metformin Hcl Er100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 1 Sept 2026
3 NIH research awards on record, funded 1993–2025 per NIH RePORTER. The latest:
- 5/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
Nathan S. Kline Institute for Psych Res
FY2025$203,625R01MH120185 - 5/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
Nathan S. Kline Institute for Psych Res
FY2024$203,625R01MH120185 - 5/7 Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
Nathan S. Kline Institute for Psych Res
FY2023$203,625R01MH120185
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia
The Journal of Clinical Psychiatry
2020 - Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia
The Journal of Clinical Psychiatry
2019 - Cognitive remediation for schizophrenia: An expert working group white paper on core techniques
Schizophrenia Research
2019
Online presence
Updated 1 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/jean-pierre-lindenmayer-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
ncbi.nlm.nih.gov/myncbi/1tss5oBHViHQF/bibliography/public
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ncbi.nlm.nih.gov ↗ - ResearchGate
researchgate.net/profile/Jean-Pierre-Lindenmayer-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
nki.rfmh.org/people/jean-pierre-lindenmayer-m-d
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nki.rfmh.org ↗ - LinkedIn
LinkedIn profile ("Director of Research, Manhattan Schizophrenia Research Program") consistent with subject's institutional identity
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 1 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Basel Faculty of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.nyu.edu ↗ - Psychiatry residency
SUNY Downstate Medical Center; Fellowship, SUNY Downstate Doctor of Medical Sciences Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.nyu.edu ↗ - Diplomate
American Board of Psychiatry and Neurology, board certified in Psychiatry
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Director
Manhattan Schizophrenia Research Program (since 1994); previously Clinical Director, Manhattan Psychiatric Center, and Director, Schizophrenia Research Program …
1994verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nki.rfmh.org ↗
Awards & honors
honors on the public record- Dr. Lewis Opler
M.D. Award, NAMI-NYS (2022), recognizing decades of mental health research and advocacy
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nki.rfmh.org ↗
Secondary affiliations
appointments beyond the home institution- Director
Manhattan Schizophrenia Research Program, Manhattan Psychiatric Center / Nathan Kline Institute for Psychiatric Research (RFMH), New York
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nki.rfmh.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Jill Buyon, MD
NYU Grossman School of Medicine
Jeffrey Berger, MD
NYU Grossman School of Medicine
Mark Mulligan, MD
NYU Grossman School of Medicine
David Goldfarb, MD
NYU Grossman School of Medicine